Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 7/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.34 |
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22043758 | 0.81 | DGAT1 (0.49) | CASP1KDM4ETP53MAPT | |
| SCHEMBL24022799 | 0.80 | TP53 (0.36) | CASP1KDM4ETP53MAPTMKNK1 | |
| SCHEMBL25511292 | 0.73 | MKNK1 (0.47) | KDM4ETP53MAPTMKNK1MKNK2 | |
| SCHEMBL30262615 | 0.71 | PARP1 (0.48) | CDK9 | |
| SCHEMBL24022840 | 0.71 | CA1 (0.48) | KDM4ETP53MAPT | |
| SCHEMBL22043755 | 0.70 | KDM4E (0.44) | KDM4ETP53MAPT | |
| SCHEMBL24022824 | 0.70 | DHODH (0.34) | KDM4ETP53MAPTMKNK1MKNK2 | |
| SCHEMBL15662716 | 0.69 | RARB (0.44) | KDM4E | |
| SCHEMBL28797442 | 0.68 | GRM2 (0.36) | MAPTCDC7 | |
| SCHEMBL22147523 | 0.68 | FAAH (0.40) | KDM4ETP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | RIGSHOSPITALET [DK]/[DK] (DK) | 2024-08-29 | — | — | US | disclosed |
| WO-2021228992-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | RIGSHOSPITALET (DK) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909944-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | Rigshospitalet (DK) | 2021-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | HUNK, NUCB2, TK1 | CASP1 1441/4885KDM4E 4344/4885TP53 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.